Andre Vivan da Silva – Country Manager, GSK Brazil
After a successful international career, Andre Vivan da Silva recently returned to his native Brazil to become GSK’s country manager. He explains the importance of vaccination, in Brazil, and HIV…
We are one of the world leaders in the creation of therapeutic solutions that help improve people’s quality of life by working on the development of innovative products in the fields of prescription drugs, vaccines and health care.
We have a significant global presence with business activities in more than 150 countries, a network of 84 production units in 36 countries and major R&D centers in the UK, USA, Spain, Belgium and China. In Brazil, we have factories in the states of São Paulo and Rio de Janeiro.
Contact:
Address: Estrada dos Bandeirantes 8464
Rio de Janeiro
RJ CEP 22783-110 or CNPJ 33.247743/0001-10
Tel.: +55 (800) 701 22 33
Website: https://br.gsk.com/
After a successful international career, Andre Vivan da Silva recently returned to his native Brazil to become GSK’s country manager. He explains the importance of vaccination, in Brazil, and HIV…
Alexei Kolchin, general manager of GSK Brazil, discusses adapting to Brazil, having previously held the equivalent role in Russia, the Brazilian affiliate’s contribution to GSK’s global growth, and its embrace…
You’ve made some bold moves in your career – from the head of vaccines in Latin America, followed by stints in Colombia, Puerto Rico, and finally Brazil. What brought you…
The Brazilian pharma market outperformed the Latin American average in Q1 of 2020 with a growth of 8.2 percent in real terms (inflation adjusted), according to IQVIA. Its size reached…
Six of the top ten companies in the Brazilian pharma market are domestic.* Read on for an introduction to some of the Brazilian giants that are perhaps less well known…
Panorama Faramceutico’s editorial team look at how the ongoing COVID-19 pandemic stands to affect Brazil’s over the counter (OTC) market segment during and after the COVID-19 pandemic.* The OTC…
In the race to develop the world’s first COVID-19 vaccine, Brazil – now one of the world’s worst-affected countries – is becoming an attractive clinical trial destination for biopharma companies…
The editorial team at Panorama Farmaceutico explain how the COVID-19 pandemic and global trade flow stoppages are impacting the manufacture and supply of medicines within Brazil.* The COVID-19 pandemic…
The editorial team at Panorama Farmaceutico explain why coordinated action is needed within Brazilian pharma to reduce dependence on API imports from abroad and increase medical sovereignty. * The…
Below we highlight recent news in Brazilian pharma, including the impact of coronavirus as well as legal and regulatory updates. Proposal to allow breaking of patents due to Covid-19…
Swiss pharma giant Novartis is teaming up with the Oswaldo Cruz Foundation (Fiocruz) in Brazil to conduct research throughout Latin America on neglected diseases. This agreement establishes an exchange…
Three seasoned pharma executives with a wealth of experience working in Brazil offer their insights on leadership strategies for success in the massive, but complex, Brazilian pharma market. …
Rodrigo Araujo of global organizational consulting firm Korn Ferry outlines what he sees as the leadership profile of the future – agile, digital, self-aware, and able to transform both themselves…
When combining the sheer size of Brazil – the fifth largest country in the world – with its tropical climate, its largely perfectible infrastructure, and the soaring importance of temperature…
“Brazil undoubtedly holds great development opportunities for the global pharmaceutical and healthcare industries,” boldly states Minister of Health Ricardo Barros, “and we hope to gain the trust of an increasing…
See our Cookie Privacy Policy Here
